Time to Tap Healthcare ETFs on Nvidia's AI Ambition?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 04 2024
0mins
Should l Buy JNJ?
Source: NASDAQ.COM
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 245.300
Low
190.00
Averages
218.50
High
240.00
Current: 245.300
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson Receives FDA Approval for New Myeloma Therapy
- Clinical Data Breakthrough: Johnson & Johnson's TECVAYLI® and DARZALEXFASPRO® combination therapy demonstrated a three-year progression-free survival rate of 83% in the MajesTEC-3 study, significantly outperforming the 30% rate of standard treatments, indicating durable clinical benefits for multiple myeloma patients.
- Establishment of New Standard: The FDA's approval positions this combination therapy as a potential new standard of care for relapsed or refractory multiple myeloma patients, particularly benefiting the 40% of patients who experience disease relapse, thereby potentially transforming clinical practice.
- Safety and Tolerability: While the combination of TECVAYLI® and DARZALEXFASPRO® showed similar rates of Grade 3/4 adverse events compared to standard treatment (95.1% vs. 96.6%), its lower toxicity profile may enhance patient tolerability and reduce the risk of treatment discontinuation.
- Broad Market Prospects: This FDA approval not only strengthens Johnson & Johnson's leadership in the multiple myeloma treatment landscape but also lays the groundwork for future market expansion and innovative treatment options, further advancing its strategic goals in hematology.
See More
FDA Approves Johnson & Johnson's Tecvayli for Multiple Myeloma Treatment
- FDA Approval: The U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's antibody therapy Tecvayli (teclistamab) in combination with Darzalex Faspro for adults with relapsed or refractory multiple myeloma, marking a significant advancement in blood cancer treatment.
- Rapid Approval Process: This approval was achieved in just 55 days after J&J received a national priority voucher in December, demonstrating the FDA's commitment to expediting the review of experimental therapies aligned with U.S. national interests, thereby enhancing J&J's competitive edge in biopharmaceuticals.
- Innovative Technology Application: Darzalex Faspro, developed using Halozyme's Enhanze drug delivery technology, when combined with Tecvayli, may offer a more effective treatment option for multiple myeloma patients, potentially improving their quality of life.
- Broad Market Prospects: This approval not only opens new market opportunities for Johnson & Johnson but may also encourage other biopharmaceutical companies to accelerate the development of similar therapies, further driving innovation and growth in the multiple myeloma sector.
See More
Johnson & Johnson Options Analysis and Yield Expectations
- Put Option Appeal: The current bid for the $235.00 put option is $4.95, and if an investor sells to open this contract, they commit to buying the stock at $235.00, effectively lowering their cost basis to $230.05, which represents about a 2% discount compared to the current price of $239.89, making it attractive for those looking to acquire JNJ shares at a lower price.
- Yield Potential Analysis: Should the put option expire worthless, the premium would yield a 2.11% return on the cash commitment, equating to an annualized return of 15.39%, indicating that utilizing options strategies can effectively enhance investment returns in the current market environment.
- Call Option Returns: The current bid for the $245.00 call option is $5.35, and if an investor buys shares at $239.89 and sells this contract, they could achieve a total return of 4.36% if the stock is called away at expiration, showcasing the potential profitability of options strategies.
- Market Volatility Considerations: Both the put and call options have an implied volatility of approximately 26%, while the actual trailing twelve-month volatility stands at 19%, suggesting a heightened market expectation for future price fluctuations of JNJ stock, prompting investors to carefully assess risk versus reward.
See More
Zyrtec Becomes PGA TOUR's Official Allergy Relief Sponsor
- Allergy Season Impact: According to the American College of Allergy, Asthma & Immunology, the U.S. spring allergy season typically runs from February to early June, with peak tree pollen levels occurring between March and mid-May, leading to increased allergy burdens for sufferers.
- Sponsorship Partnership: Zyrtec has recently become the PGA TOUR's first official
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a robust annual growth rate of approximately 9%, driven by increasing awareness of mental health and demand for innovative solutions.
- Diverse Treatment Options: In addition to traditional anti-anxiety and antidepressant medications, the rise of cognitive-behavioral therapy and digital mental health tools has enhanced accessibility and effectiveness, allowing patients to manage symptoms in more flexible ways.
- Helus Pharma Drug Development: Helus Pharma announced positive topline results from its Phase 2 signal detection study for HLP004, indicating significant potential for this treatment to benefit adults with moderate-to-severe GAD who have not responded to existing therapies, thus offering new hope for underserved patients.
- Investment Outlook: As mental health care becomes increasingly integrated into mainstream healthcare systems, the broader anxiety treatment market is expected to exceed $12 billion in the next decade, with ongoing investments from companies and investors likely to drive long-term growth in this sector.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for generalized anxiety disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a 9% annual growth rate driven by increasing awareness of mental health and demand for innovative solutions.
- Therapeutic Innovation: Helus Pharma's HLP004 demonstrated significant efficacy in a Phase 2 clinical trial for moderate-to-severe GAD patients, achieving an average reduction of 10.4 points in the Hamilton Anxiety Rating Scale (p<0.0001) within six weeks, offering new hope for patients who have not responded to existing treatments.
- Positive Patient Response: At six months, 67% of participants showed treatment response and 39% achieved remission, indicating that HLP004 provides durable effects and could potentially transform the treatment landscape for GAD.
- Optimistic Industry Outlook: The rise of digital mental health tools and telehealth has significantly improved treatment accessibility, and investments by Helus Pharma and other companies in mental health solutions are expected to drive continued market growth to meet the increasing patient demand.
See More
Johnson & Johnson Receives FDA Approval for New Myeloma Therapy
- Clinical Data Breakthrough: Johnson & Johnson's TECVAYLI® and DARZALEXFASPRO® combination therapy demonstrated a three-year progression-free survival rate of 83% in the MajesTEC-3 study, significantly outperforming the 30% rate of standard treatments, indicating durable clinical benefits for multiple myeloma patients.
- Establishment of New Standard: The FDA's approval positions this combination therapy as a potential new standard of care for relapsed or refractory multiple myeloma patients, particularly benefiting the 40% of patients who experience disease relapse, thereby potentially transforming clinical practice.
- Safety and Tolerability: While the combination of TECVAYLI® and DARZALEXFASPRO® showed similar rates of Grade 3/4 adverse events compared to standard treatment (95.1% vs. 96.6%), its lower toxicity profile may enhance patient tolerability and reduce the risk of treatment discontinuation.
- Broad Market Prospects: This FDA approval not only strengthens Johnson & Johnson's leadership in the multiple myeloma treatment landscape but also lays the groundwork for future market expansion and innovative treatment options, further advancing its strategic goals in hematology.
See More
FDA Approves Johnson & Johnson's Tecvayli for Multiple Myeloma Treatment
- FDA Approval: The U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's antibody therapy Tecvayli (teclistamab) in combination with Darzalex Faspro for adults with relapsed or refractory multiple myeloma, marking a significant advancement in blood cancer treatment.
- Rapid Approval Process: This approval was achieved in just 55 days after J&J received a national priority voucher in December, demonstrating the FDA's commitment to expediting the review of experimental therapies aligned with U.S. national interests, thereby enhancing J&J's competitive edge in biopharmaceuticals.
- Innovative Technology Application: Darzalex Faspro, developed using Halozyme's Enhanze drug delivery technology, when combined with Tecvayli, may offer a more effective treatment option for multiple myeloma patients, potentially improving their quality of life.
- Broad Market Prospects: This approval not only opens new market opportunities for Johnson & Johnson but may also encourage other biopharmaceutical companies to accelerate the development of similar therapies, further driving innovation and growth in the multiple myeloma sector.
See More
Johnson & Johnson Options Analysis and Yield Expectations
- Put Option Appeal: The current bid for the $235.00 put option is $4.95, and if an investor sells to open this contract, they commit to buying the stock at $235.00, effectively lowering their cost basis to $230.05, which represents about a 2% discount compared to the current price of $239.89, making it attractive for those looking to acquire JNJ shares at a lower price.
- Yield Potential Analysis: Should the put option expire worthless, the premium would yield a 2.11% return on the cash commitment, equating to an annualized return of 15.39%, indicating that utilizing options strategies can effectively enhance investment returns in the current market environment.
- Call Option Returns: The current bid for the $245.00 call option is $5.35, and if an investor buys shares at $239.89 and sells this contract, they could achieve a total return of 4.36% if the stock is called away at expiration, showcasing the potential profitability of options strategies.
- Market Volatility Considerations: Both the put and call options have an implied volatility of approximately 26%, while the actual trailing twelve-month volatility stands at 19%, suggesting a heightened market expectation for future price fluctuations of JNJ stock, prompting investors to carefully assess risk versus reward.
See More
Zyrtec Becomes PGA TOUR's Official Allergy Relief Sponsor
- Allergy Season Impact: According to the American College of Allergy, Asthma & Immunology, the U.S. spring allergy season typically runs from February to early June, with peak tree pollen levels occurring between March and mid-May, leading to increased allergy burdens for sufferers.
- Sponsorship Partnership: Zyrtec has recently become the PGA TOUR's first official
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a robust annual growth rate of approximately 9%, driven by increasing awareness of mental health and demand for innovative solutions.
- Diverse Treatment Options: In addition to traditional anti-anxiety and antidepressant medications, the rise of cognitive-behavioral therapy and digital mental health tools has enhanced accessibility and effectiveness, allowing patients to manage symptoms in more flexible ways.
- Helus Pharma Drug Development: Helus Pharma announced positive topline results from its Phase 2 signal detection study for HLP004, indicating significant potential for this treatment to benefit adults with moderate-to-severe GAD who have not responded to existing therapies, thus offering new hope for underserved patients.
- Investment Outlook: As mental health care becomes increasingly integrated into mainstream healthcare systems, the broader anxiety treatment market is expected to exceed $12 billion in the next decade, with ongoing investments from companies and investors likely to drive long-term growth in this sector.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for generalized anxiety disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a 9% annual growth rate driven by increasing awareness of mental health and demand for innovative solutions.
- Therapeutic Innovation: Helus Pharma's HLP004 demonstrated significant efficacy in a Phase 2 clinical trial for moderate-to-severe GAD patients, achieving an average reduction of 10.4 points in the Hamilton Anxiety Rating Scale (p<0.0001) within six weeks, offering new hope for patients who have not responded to existing treatments.
- Positive Patient Response: At six months, 67% of participants showed treatment response and 39% achieved remission, indicating that HLP004 provides durable effects and could potentially transform the treatment landscape for GAD.
- Optimistic Industry Outlook: The rise of digital mental health tools and telehealth has significantly improved treatment accessibility, and investments by Helus Pharma and other companies in mental health solutions are expected to drive continued market growth to meet the increasing patient demand.
See More
